BRCA1与BRCA2序列变异女性的MRI监测与乳腺癌死亡率
该队列研究纳入11国59个中心的2488例BRCA1或BRCA2序列变异女性,比较进入MRI监测计划与未进入者的乳腺癌死亡率。中位随访9.2年后,BRCA1变异者中MRI监测与乳腺癌死亡率显著降低相关(HR 0.20),BRCA2变异者中关联不显著(HR 0.87),作者认为BRCA2女性需进一步研究。
要点
- BRCA1序列变异女性中,进入MRI监测计划与乳腺癌死亡率显著降低相关(HR 0.20,95%CI 0.10-0.43)。
- BRCA2序列变异女性中,MRI监测与乳腺癌死亡率的关联未达统计学显著(HR 0.87,95%CI 0.10-17.25)。
- 作者认为BRCA2序列变异女性是否获得相同获益需进一步研究。
核心结论
- 在BRCA1序列变异女性中,MRI监测与乳腺癌死亡率显著降低相关(HR 0.20,95%CI 0.10-0.43;P < .001)。
- 在BRCA2序列变异女性中,MRI监测与乳腺癌死亡率的关联未达统计学显著(HR 0.87,95%CI 0.10-17.25;P = .93)。
- 作者认为需进一步研究以确定BRCA2序列变异女性是否获得与MRI监测相关的相同获益。
研究设计与样本
- 队列研究,纳入11个国家59个参与中心的BRCA1或BRCA2序列变异女性。
- 参与者于1995年至2015年间完成基线问卷,此后每2年完成一次随访问卷,记录筛查史、新发癌症和生命状态。
- 排除入组前已患乳腺癌、已行筛查MRI检查或双侧乳房切除术的女性。
- 随访从30岁(或基线问卷日期,以较晚者为准)至75岁、末次随访或乳腺癌死亡。
- 共纳入2488例女性(平均[范围]入组年龄41.2[30-69]岁),其中BRCA1变异2004例、BRCA2变异484例。
主要发现
- 1756例(70.6%)至少进行过1次筛查MRI检查,732例(29.4%)未进行。
- 平均随访9.2年后,344例(13.8%)发生乳腺癌,35例(1.4%)死于乳腺癌。
- BRCA1序列变异女性中,进入MRI监测计划与乳腺癌死亡率的年龄校正HR为0.20(95%CI 0.10-0.43;P < .001)。
- BRCA2序列变异女性中,进入MRI监测计划与乳腺癌死亡率的年龄校正HR为0.87(95%CI 0.10-17.25;P = .93)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Magnetic resonance imaging (MRI) surveillance is offered to women with a pathogenic variant in the BRCA1 or BRCA2 gene who face a high lifetime risk of breast cancer. Surveillance with MRI is effective in downstaging breast cancers, but the association of MRI surveillance with mortality risk has not been well defined. OBJECTIVE: To compare breast cancer mortality rates in women with a BRCA1 or BRCA2 sequence variation who entered an MRI surveillance program with those who did not. DESIGN, SETTING, AND PARTICIPANTS: Women with a BRCA1 or BRCA2 sequence variation were identified from 59 participating centers in 11 countries. Participants completed a baseline questionnaire between 1995 and 2015 and a follow-up questionnaire every 2 years to document screening histories, incident cancers, and vital status. Women who had breast cancer, a screening MRI examination, or bilateral mastectomy prior to enrollment were excluded. Participants were followed up from age 30 years (or the date of the baseline questionnaire, whichever was later) until age 75 years, the last follow-up, or death from breast cancer. Data were analyzed from January 1 to July 31, 2023. EXPOSURES: Entrance into an MRI surveillance program. MAIN OUTCOMES AND MEASURES: Cox proportional hazards modeling was used to estimate the hazard ratios (HRs) and 95% CIs for breast cancer mortality associated with MRI surveillance compared with no MRI surveillance using a time-dependent analysis. RESULTS: A total of 2488 women (mean [range] age at study entry 41.2 [30-69] years), with a sequence variation in the BRCA1 (n = 2004) or BRCA2 (n = 484) genes were included in the analysis. Of these participants, 1756 (70.6%) had at least 1 screening MRI examination and 732 women (29.4%) did not. After a mean follow-up of 9.2 years, 344 women (13.8%) developed breast cancer and 35 women (1.4%) died of breast cancer. The age-adjusted HRs for breast cancer mortality associated with entering an MRI surveillance program were 0.20 (95% CI, 0.10-0.43; P < .001) for women with BRCA1 sequence variations and 0.87 (95% CI, 0.10-17.25; P = .93) for women with BRCA2 sequence variations. CONCLUSION AND RELEVANCE: Results of this cohort study suggest that among women with a BRCA1 sequence variation, MRI surveillance was associated with a significant reduction in breast cancer mortality compared with no MRI surveillance. Further studies of women with BRCA2 sequence variations are needed to ascertain these women obtain the same benefits associated with MRI surveillance.
引用
- Lubinski J, Kotsopoulos J, Moller P, et al. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncol. 2024. PMID: 38421676. doi:10.1001/jamaoncol.2023.6944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。